About the Company
Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EVFM News
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to ...
Evofem Biosciences Inc EVFM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Aditxt Announces Merger Agreement with Evofem Biosciences
Aditxt, Inc. has entered into a Merger Agreement with its subsidiary Adicure, Inc. and Evofem Biosciences, Inc., with ...
Evofem Biosciences (OTC: EVFM)
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health.
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: Delivered $18.2 ...
Evofem set to secure fifth US patent for Phexxi contraceptive
SAN DIEGO - Evofem Biosciences, Inc. (OTCQB: OTC:EVFM) is on the cusp of obtaining its fifth US patent for Phexxi, a hormone-free contraceptive gel, following a Notice of Allowance from the United ...
HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...
Evofem Biosciences Inc EVFM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire ...
Evofem Biosciences Inc (EVFM)
Evofem Biosciences (NASDAQ:EVFM) has been taking steps to increase awareness about its FDA-approved product—Phexxi. However, the stock has been losing value over the past... Investing.com – U ...
Evofem Biosciences Inc (EVFM)
All relevant comments and Evofem Biosciences Inc share chat regarding the EVFM OTC share news are listed here in the EVFM forum. View and contribute to the EVFM share chat. Discuss Evofem Biosciences ...
Loading the latest forecasts...